EscharEx 5% (EX-02 formulation)
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Superficial Basal Cell Carcinoma
Conditions
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Trial Timeline
Jun 30, 2021 → Jun 1, 2022
NCT ID
NCT05157763About EscharEx 5% (EX-02 formulation)
EscharEx 5% (EX-02 formulation) is a phase 1/2 stage product being developed by MediWound for Superficial Basal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05157763. Target conditions include Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05157763 | Phase 1/2 | Recruiting |
Competing Products
11 competing products in Superficial Basal Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | enGene | Phase 1/2 | 33 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Diclofenac gel | Novartis | Approved | 85 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Dalteparin sodium injection | Pfizer | Approved | 84 |
| Rivaroxaban + Fondaparinux | Bayer | Phase 3 | 74 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Chemophase | Halozyme Therapeutics | Phase 1 | 30 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 69 |